Skip to main content
. 2016 Jan 7;3(1):e191. doi: 10.1212/NXI.0000000000000191

Figure 3. LCN2 correlation to NFL and natalizumab treatment effect on CSF LCN2 levels in SPMS.

Figure 3

(A) Correlation between neurofilament light (NFL) and lipocalin-2 (LCN2) index in secondary progressive multiple sclerosis (SPMS). (B) Effect of 6 months of treatment with natalizumab on CSF LCN2 levels in progressive multiple sclerosis. ****p < 0.0001.